礼来公司近日发布公开信,针对替尔泊肽与维生素B12复方制剂可能引发的患者安全风险发出警示。该公司强调,此类未经严格监管的复方药物存在重大安全隐患,呼吁医疗从业者和患者保持警惕。
礼来公司近日发布公开信,针对替尔泊肽与维生素B12复方制剂可能引发的患者安全风险发出警示。该公司强调,此类未经严格监管的复方药物存在重大安全隐患,呼吁医疗从业者和患者保持警惕。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.